PRIMARY OBJECTIVES:
I. Determine the safety and tolerability of talazoparib given in combination with gemtuzumab
ozogamicin therapy in adult patients with relapsed and/or refractory acute myeloid leukemia
(AML).
II. Determine the overall response rate (ORR consisting of complete remission [CR] or
complete remission with incomplete hematologic recovery [CRi]) of combination therapy with
talazoparib and gemtuzumab ozogamicin in patients with relapsed and/or refractory AML.
SECONDARY OBJECTIVE:
I. Evaluate the preliminary anti-leukemic efficacy of talazoparib given in combination with
gemtuzumab ozogamicin as determined by complete remission (CR) rate, best response rate (CRi
+ partial remission [PR]), duration of remission, leukemia-free survival (LFS), transfusion
independence (TI), and overall survival (OS) in patients treated with this combination
therapy.
EXPLORATORY OBJECTIVES:
I. Evaluate the efficacy of talazoparib given in combination with gemtuzumab ozogamicin on
minimal residual disease (MRD) in treated patients.
II. Evaluate mechanistic biomarkers including levels of PARP inhibition and deoxyribonucleic
acid (DNA) damage effects in peripheral blood and marrow samples from patients treated with
combination therapy.
III. Evaluate quality of life (QOL) of patients with relapsed/refractory AML treated with
talazoparib and gemtuzumab ozogamicin.
IV. Evaluate the number of patients able to proceed onto subsequent hematopoietic stem cell
transplantation (HSCT) following combination therapy.
OUTLINE: This is a dose-escalation study of talazoparib.
Patients receive talazoparib orally (PO) daily on days 1-21 and gemtuzumab ozogamicin
intravenously (IV) over 2 hours on days 1, 4, and 7 or day 1 for patients who CR/CRi after
cycles 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease
progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then every 3 months
for up to 12 months.
Inclusion Criteria:
- Eastern Cooperative Oncology Group performance status between 0-2
- Creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance
(Cockcroft and Gault ) > 30 mL/min (performed on plasma unless otherwise indicated)
- Alanine aminotransferase (ALT) =< 2.5 x ULN (performed on plasma unless otherwise
indicated)
- Direct bilirubin < 1.5 mg/dL (performed on plasma unless otherwise indicated)
- Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO)
or multiple-gated acquisition (MUGA) scan performed within 28 days of enrollment
- Diagnosis of CD33+ acute myeloid leukemia (AML) with evidence of >= 5% myeloblasts in
the bone marrow, peripheral blood, or in an extramedullary site by pathology. Any CD33
receptor expression level > 0.01% by institute flow cytometric analysis will suffice
- Relapsed or refractory disease, defined as:
- Any bone marrow relapse after allogeneic HSCT: subjects must be at least 1 month
from HSCT at the time of screening and off immunosuppressive medication for at
least 2 weeks at time of initial treatment (with the exception of low-dose
steroids =< 20 mg prednisone equivalent) and have no active graft versus (vs.)
host disease (GVHD)
- AML with no prior CR/CRi after at least 1 prior cycle of remission induction
chemotherapy (i.e. cytarabine or hypomethylating based regimen(s) allowed)
- AML recurring after prior CR/CRi, which was achieved following at least one prior
chemotherapy cycle (i.e. cytarabine or hypomethylating based regimen(s) allowed)
- Participants of childbearing potential must agree to use adequate contraceptive
methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study
entry. Should a woman become pregnant or suspect she is pregnant while she or her
partner is participating in this study, she should inform her treating physician
immediately
- Participant must understand the investigational nature of this study and sign an
Independent Ethics Committee/Institutional Review Board approved written informed
consent form prior to receiving any study related procedure
Exclusion Criteria:
- Acute promyelocytic leukemia (APL, FAB M3) with t(15-17) and/or evidence of
promyelocytic leukemia/retinoic acid receptor alpha (PML-RAR alpha)
- Blast phase of prior chronic phase chronic myeloid leukemia with t(9;22)
- Receipt of chemotherapy (except for hydroxyurea), radiotherapy, or investigational
drug therapy within 2 weeks prior to treatment on study or those who have not
recovered from adverse events due to agents administered > 2 weeks earlier
- Known active central nervous system involvement; patients who have a history of
central nervous system (CNS) disease which has been effectively treated as defined by
at least one negative cerebrospinal sample prior to screening are eligible
- Active uncontrolled malignancy requiring ongoing chemotherapy and/or radiation.
Examples of eligible patients include individuals with a prior history of malignancy
treated with curative intent with no current evidence of active disease such as:
- Subjects with stage I breast cancer that has been completely and successfully
treated, requiring no therapy or only anti-hormonal therapy
- Subjects with T1N0M0 or T2N0M0 colorectal cancer who have been completely and
successfully resected and who are disease-free for > 2 years prior to screening
- Subjects with indolent prostate cancer, defined as clinical stage T1 or T2a,
Gleason score =< 6, and prostate specific antigen (PSA) < 10 ng/mL, requiring no
therapy or only anti-hormonal therapy
- Subjects with a history of basal cell or squamous cell carcinoma of the skin, or
carcinoma in situ of the cervix, fully resected, and with no evidence of active
disease
- Other prior or concurrent malignancies will be considered on a case-by-case basis
after discussion with the principal investigator (PI)
- Uncontrolled current medical illness including, but not limited to, symptomatic
congestive heart failure, unstable angina pectoris, myocardial infarction, cardiac
arrhythmia, torsades de pointes, cerebrovascular accident, transient ischemic attack,
or psychiatric illness/social situations that in the opinion of the investigator would
limit compliance with study requirements
- Known malabsorption syndrome or other condition that may impair the absorption of the
study drug and/or inability and/or unwillingness to swallow capsules
- Uncontrolled active systemic fungal, bacterial, viral, or other infection with patient
still exhibiting ongoing signs and symptoms due to infection despite appropriate
anti-infective therapy at time of screening
- Pregnant or breastfeeding female participants
- Known active hepatitis B, active hepatitis C, or any human immunodeficiency virus
(HIV) infection at the time of screening which requires therapy
- Presence of grade II-IV acute or extensive chronic GVHD at time of screening
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator's opinion deems the participant an unsuitable
candidate to receive study drug including, but not limited to, medical, psychological,
familial, social or geographical considerations